Neurotrophic peptides
View Patent ↗The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VGDGGLFEKKL (SEQ ID NO: 1), EDQQVHFTPTEG (SEQ ID NO: 2) and IPENEADGMPATV (SEQ ID NO: 3).
1. An isolated neurotrophic peptide consisting of the amino acid sequence VGDGGLFEKKL (SEQ ID NO: 1).
2. A pharmaceutical composition comprising a neurotrophic peptide consisting of the amino acid sequence GDGGLFEK (SEQ ID NO: 5), GLFEKKLW (SEQ ID NO: 6), VGDG (SEQ ID NO: 7), DGGL (SEQ ID NO: 9), or GGLF (SEQ ID NO: 10) in a pharmaceutically acceptable excipient and/or carrier.
3. The composition of claim 2 , wherein the composition is suitable for intravenous, intramuscular, spinal, epidural, transdermal, subcutaneous, parenteral, intranasal, mucosal, oral, enteral, and/or rectal administration.
4. The composition of claim 2 , wherein the composition is a slow release formulation.
5. The composition of claim 2 , wherein the peptide is comprised in the composition in an amount between 0.1 μg/g to 100 mg/g.
6. The composition of claim 5 , wherein the peptide is comprised in the composition in an amount between 1 μg to 80 mg/g.
7. A method of treating a subject comprising:
obtaining a pharmaceutical composition of claim 2 ; and
providing the composition to a subject;
wherein a learning-memory capacity is improved in the subject, and/or neurogenesis is promoted in the subject.
8. The method of claim 7 , wherein learning-memory capacities are improved in the subject.
9. The method of claim 7 , wherein the composition further comprises at least one additional pharmaceutically active component.
10. The method of claim 7 , wherein the composition is provided intravenously, intramuscularly, spinally, epidurally, intranasally, mucosally, transdermally, subcutaneously, parenterally, orally, enterally, or rectally.
11. The method of claim 7 , wherein the composition is a slow release formulation.
12. The method of claim 7 , wherein the composition comprises the peptide in an amount between 0.1 μg/g to 100 mg/g.
13. The method of claim 12 , wherein the composition comprises the peptide in an amount between preferably 1 μg to 80 mg/g.
14. The method of claim 13 , wherein the peptide is administered to the subject at a dose of 0.1 μg/kg to 20 mg/kg body weight.
15. The method of claim 14 , wherein the peptide is administered to the subject at a dose of 0.5 μg/kg to 10 mg/kg body weight.
16. The method of claim 7 , wherein the subject is a human.